Litcius/Paper detail

Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4·5 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial

Shuya Li, Hongqiu Gu, Baoyu Feng, Hao Li, Xuechun Wang, Qiang Dong, Dongsheng Fan, Yun Xu, Suiqiang Zhu, Hongguo Dai, Yan Wei, Ziran Wang, Guozhi Lu, Yutong Ma, Zixiao Li, Yilong Wang, Meng Xia, Xingquan Zhao, Liping Liu, Yongjun Wang, Yongjun Wang, Yongjun Wang

2024The Lancet Neurology42 citationsDOI

Topics & Concepts

Open labelStroke (engine)MedicineIschaemic strokeClinical trialRecombinant DNAIschemic strokeAnesthesiaInternal medicineIschemiaGeneBiologyBiochemistryEngineeringMechanical engineeringAcute Ischemic Stroke ManagementProtease and Inhibitor MechanismsBlood properties and coagulation
Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4·5 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial | Litcius